IPO
Relay Therapeutics was the No. 3 company in BioSpace’s NextGen Bio Class of 2018, Top 20 Life Science Startups to Watch in 2018.
The company is focused on developing cell and gene therapies based on a proprietary DNA modification, gene editing and delivery technology.
BioSpace takes a look at some of the most recent IPO plans from companies across the globe.
Philadelphia, PA – Oncoceutics announced a Brown University award of $3.4 million that will be used to support a group of research teams for preclinical research, IND-enabling studies and a first-in-human clinical trial for Oncoceutics’ imipridone ONC212.
In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share, which would result in raising up to $1.96 billion for its initial public offering.
Three months after hearing loss-focused company Akouos secured $105 million in a Series B financing round, the Boston-based company is eying an initial public offering valued at about $100 million.
Legend Biotech, a clinical stage oncology biotech company, filed with the U.S. Securities and Exchange Commission on Wednesday to raise up to $100 million in an initial public offering.
Four months after raising $30 million in a Series C financing round, Watertown, Mass.-based Lyra Therapeutics raised an additional $56 million in its initial public offering.
Company enters next development phase with management expansion and implementation of a Strategic and Scientific Advisory Board
Heidelberg Pharma AG announces that it has successfully raised approximately EUR 14.4 million in gross proceeds through a private placement via an accelerated book building transaction.
PRESS RELEASES